Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

DGAP-Adhoc: Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE

eqs_en 
0 0 10.09.20
DGAP-Adhoc: Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE
 

DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Alliance
Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE

10-Sep-2020 / 14:48 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Disclosure of Insider Information pursuant to Section 17 (1) 1 of the Regulation (EU)
No. 596/2014 on Market Abuse, as amended
(Market Abuse Regulation - MAR)

 

Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE

Grünwald, September 10, 2020 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) and BioNTech SE, Mainz, Germany, have agreed that their production subsidiaries will cooperate on producing a COVID-19 vaccine. The production capacities at Dermapharm will be available to the cooperation partners BioNTech SE and Pfizer Inc. already when production of the vaccine begins.

>End of the ad hoc announcement<

 

Contacts

 

Investor Relations &
Corporate Communications
Britta Hamberger
Phone: +49 (0)89 - 64186-233
Fax: +49 (0)89 - 64186-165
e-mail: [email protected]
cometis AG
Claudius Krause
Phone: +49 (0)611 - 205855-28
Fax: +49 (0)611 - 205855-66
e-mail: [email protected]
 

 

 

10-Sep-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany
Phone: +49 (0)89 64 86-0
E-mail: [email protected]
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1129961

 
End of Announcement DGAP News Service

1129961  10-Sep-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1129961&application_name=news&site_id=sharewise

Dermapharm Holding SE Stock

€32.75
-1.360%
We can see a decrease in the price for Dermapharm Holding SE. Compared to yesterday it has lost -€0.450 (-1.360%).
Currently there is a rather positive sentiment for Dermapharm Holding SE with 5 Buy predictions and 0 Sell predictions.
With a target price of 55 € there is a hugely positive potential of 67.94% for Dermapharm Holding SE compared to the current price of 32.75 €.
Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Not a member yet? Sign up for free!